Hutchison MediPharma Limited Initiates Phase I Clinical Trial of HMPL-011, Its Novel Single Chemical Drug Candidate for the Treatment of Auto-immune Diseases // Chi-Med
AIM: £34.25 (+0.75) | Nasdaq: $22.25 (+0.30)
News Archive
Previous Article   |   Next Article
Innovation Platform, RNS Announcements | 30 Oct 2009

Hutchison MediPharma Limited Initiates Phase I Clinical Trial of HMPL-011, Its Novel Single Chemical Drug Candidate for the Treatment of Auto-immune Diseases

1 Item
a091030